Rotigotin

Die Aminotetralinstruktur von Rotigotin entspricht der von Dopamin, ist aber starrer

(–)-(S)-6-[Propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol

1 Weblinks

Mele B, Van S, Holroyd-Leduc J, Ismail Z, Pringsheim T, Goodarzi Z. Diagnosis, treatment and management of apathy in Parkinson's disease: a scoping review. BMJ Open. 2020;10(9):e037632

Alonso Cánovas A, Luquin Piudo R, García Ruiz-Espiga P, Burguera JA, Campos Arillo V, Castro A, Linazasoro G, López Del Val J, Vela L, Martínez Castrillo JC. Dopaminergic agonists in Parkinson's disease. Neurologia. 2014 May;29(4):230-41. English, Spanish

Zhou CQ, Li SS, Chen ZM, Li FQ, Lei P, Peng GG. Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis. PLoS One. 2013;8(7):e69738 doi:10.1371/journal.pone.0069738

Chen F, Jin L, Nie Z. Safety and Efficacy of Rotigotine for Treating Parkinson's Disease: A Meta-Analysis of Randomised Controlled Trials. J Pharm Pharm Sci. 2017;20(0):285-294 doi: 10.18433/J3Q35D. PMID: 28810946.

Rosa-Grilo M, Qamar MA, Taddei RN, Pagonabarraga J, Kulisevsky J, Sauerbier A, Chaudhuri KR. Rotigotine transdermal patch and sleep in Parkinson's disease: where are we now? NPJ Parkinsons Dis. 2017 Sep 5;3:28

Binde CD, Tvete IF, Gåsemyr JI, Natvig B, Klemp M. 2020 Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis. Eur J Clin Pharmacol. 76(12):1731-1743

2 Quelle

Rotigotine karmel(es)